Jürgen Koscielny

Learn More
We investigated the association between cerebral venous thrombosis and hereditary resistance to activated protein C (APC) in 12 consecutive German patients with non-fatal cerebral venous thrombosis and in 187 controls without a history of thrombotic disorder. Three patients (25%) had a mutation in the factor V Leiden gene against only one subject in the(More)
BACKGROUND The purpose of this study was to determine the role of recombinant activated factor VII (rFVIIa) in abdominal, vascular, and urological surgery. METHODS We conducted meta-analyses of case series and placebo-controlled studies reporting on the treatment or prophylaxis of bleeding with rFVIIa regarding 'reduction or cessation of bleeding',(More)
Rivaroxaban is an oral, direct Factor Xa inhibitor, approved for the prevention and treatment of several thromboembolic disorders. Rivaroxaban does not require routine coagulation monitoring and has a short half-life. However, confirmation of rivaroxaban levels may be required in circumstances such as life-threatening bleeding or perioperative management.(More)
Zusammenfassung Wir präsentieren eine große prospektiveUntersuchung, in dervor großenelektivenoperativen Eingriffen nach Hä-mostasestörungenein Screening erfolgte. 5649 erwachse-ne, nichtselektierte Patienten (2631Frauen, 3018 Män-ner)wurdenüberein Jahr im UniversitätsklinikumCharité untersucht. Ein standardisierter Fragebogenmit 12 Fragen wurde benutzt.(More)
INTRODUCTION Desmopressin (DDAVP) testing (DT) in patients (pts) with haemophilia A (HA) and carriers (CHA) is up to now not standardized. This prompted us to evaluate results of DT carried out between 1996 and 2011 in centres of the Competence Network Haemorrhagic Diatheses East. PATIENTS AND METHOD An increase of the factor VIII activity (FVIII) above(More)
  • 1